Related Experiment Video

Updated: Apr 19, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma

Xiaoguang Zhou1, Yanis Tolstov1, Aysenur Arslan1

  • 1Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.

Neoplasia (New York, N.Y.)
|December 16, 2014
PubMed

Insights

Renal cell carcinoma (RCC) resists DNA damage by disrupting the p53-PUMA pathway. Reactivating PUMA expression with HDAC inhibitors resensitizes RCC cells to DNA-damaging therapies, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Resistance to DNA damage-induced apoptosis is a key challenge in cancer therapy, particularly in renal cell carcinoma (RCC).
  • Understanding the molecular basis of this resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To investigate the mechanisms of DNA damage resistance in RCC.
  • To identify strategies for resensitizing RCC cells to DNA-damaging agents.

Main Methods:

  • Analysis of the p53-PUMA signaling axis in apoptosis-resistant RCC cells.
  • Investigating the role of chromatin compaction and CCCTC-binding factor (CTCF).
  • Assessing the effects of HDAC inhibitors and PUMA re-expression on RCC cell sensitivity.

Main Results:

  • Apoptosis-resistant RCC cells exhibit a disconnect between p53 activation and PUMA upregulation, attributed to aberrant chromatin compaction.
  • HDAC inhibitor treatment restored PUMA expression and resensitized RCC cells to DNA damage.
  • Ectopic PUMA expression or p53 knockdown sensitized RCC cells to genotoxic stress.

Conclusions:

  • DNA damage resistance in RCC is linked to the p53-PUMA axis and aberrant chromatin.
  • This resistance is potentially reversible and targetable, offering a promising therapeutic avenue for RCC patients.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K